Spyglass Pharma develops an IOL-mounted, controlled release drug delivery platform for delivering multiple years of therapy. The company is targeting a 3-year delivery of bimatoprost to treat glaucoma in patients undergoing cataract surgery.

Spyglass Pharma

SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.

New Enterprise Associates

RA Capital Management

Vensana Capital

Vertex Ventures HC

Samsara BioCapital

SpyGlass Pharma, Inc.

We are thrilled to announce the arrival of our first-ever class of interns! 🔬🛠️

Please join us in welcoming: Andrew, Grayson, Jose, and Rupin!

These talented individuals are diving right into high-impact process optimization and method development projects with our R&D Process Development Team. They are applying the theories and concepts they've learned in their coursework on mechanical design, heat transfer, and fluid dynamics to practical, real-world applications that will drive innovation at SpyGlass.

A special thank you to Craig Cable and Ashley Lara (pictured) for their exceptional efforts in facilitating and supporting our internship program. 

We look forward to the contributions and fresh perspectives that Andrew, Grayson, Jose, and Rupin will bring to our team!

We continue to innovate at the intersection of #cataract surgery and #glaucoma treatment. Our vision is to provide patients with an innovative new treatment option designed to deliver multiple years of IOP-lowering therapy at the time of routine #cataract surgery. 

Learn More: https://lnkd.in/gZRZ77zA

#CataractAwarenessMonth

👀 Are you ready to make a difference in eye care? 👀

At SpyGlass Pharma, Inc. we're on a mission to develop life-changing treatment options for patients suffering from ophthalmic diseases. 

Together we work toward our singular focus: Long-term drug delivery—that lasts.

We are currently seeking passionate individuals to fill the following roles:

⭐ Associate Director, Analytical R&D: (https://lnkd.in/dfW5k8Q2) 
 
⭐ Associate Director, Pharmaceutical Development: (https://lnkd.in/dRE8a7YA)

⭐ Project Manager, CMC: (https://lnkd.in/diMk-k8H)
 
⭐ Director, Quality Assurance: (https://lnkd.in/diz8hd9s) 

⭐ Director, Regulatory Affairs: (https://lnkd.in/dpuhBu4D) 

⭐ Office Manager: (https://lnkd.in/dUQKhwFw) 

⭐ Scientist, Pharmaceutical Development: (https://lnkd.in/dSKTgWAi) 

If you're looking for a challenging yet rewarding career in a dynamic and innovative environment, SpyGlass Pharma is the place for you. 

Join us in shaping the future of ophthalmic care, apply now!

We enjoyed attending American Society of Cataract and Refractive Surgery (ASCRS) and the opportunity to present the promising data of our innovative drug delivery platform. Hear from our Chief Medical Officer, Dr. Margot Goodkin, on the promising impact of the technology on the #glaucoma community. #ASCRS2024

Attending the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting? Check out the attendee tote bags for solar eclipse glasses to safely view the eclipse on April 8 from the team at SpyGlass Pharma. Snap a selfie wearing your glasses and share with us using #ASCRS2024 and #SpyglassPharma.

#Eclipse #SolarEclipse

We are proud to announce our compelling 1-year follow-up data in a first-in-human study of our intraocular drug delivery platform implanted during routine #cataract surgery in eyes with #glaucoma.

https://lnkd.in/gTi2XT9A

We are excited to welcome Margot G. and Bilal Khan to our team at SpyGlass Pharma! Their experience and expertise in #ophthalmology will help drive our singular focus forward: long-term drug delivery – that lasts. Read more: https://bit.ly/3Na2I4o

We are excited to announce the initiation of our Phase I/II clinical trial investigating our intraocular drug delivery platform in patients with #glaucoma and visually significant #cataracts. Learn more: https://bit.ly/3FCvNBx.

Thank you to The Ophthalmologist for telling our story as we strive to bring meaningful innovation to cataract surgeons managing glaucoma patients. Read more about our journey to create a platform with long-term drug delivery – that lasts: https://bit.ly/3ZCrEX8.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 25, 2024 7:26 PM	a865d540
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 25, 2024 7:26 PM	f6ca566e
translate crunchbase fundingrounds	general
peers	general	Aug 25, 2024 7:26 PM	e0c1d0be
news basic	general	Aug 25, 2024 7:26 PM	42b08a4d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SPYG

COM:SPYGLASSPHARMA

Spyglass Pharma